• XMT-2056, an Immunosynthen STING-agonist ADC targeting HER2, leverages an antibody that binds to a different epitope compared to that of trastuzumab and pertuzumab. • XMT-2056 …

XMT-2056 is a systemically-administered Immunosynthen STING agonist antibody drug conjugate (DAR 8) that is designed to target a novel HER2 epitope (distinct from pertuzumab and …

2023年3月13日 · The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors …

2025年3月3日 · Results: XMT-2056 achieved tumor-targeted delivery of the STING agonist upon systemic administration in mice and induced innate anti-tumor immune responses; single dose …

•XMT-2056 induces STING pathway and cancer cell killing activity in co-cultures of PBMCs and cancer cells expressing both high and very low levels of HER2 in vitro. •XMT-2056 is …

2023年4月4日 · XMT-2056 is a systemically administered Immunosynthen STING agonist antibody-drug conjugate (ADC) that targets a novel HER2 epitope and induces complete …

Upon intravenous administration of anti-HER2 STING agonist ADC XMT-2056, the anti-HER2 antibody moiety targets and binds to HER2 while the STING agonist targets and binds to …

2023年10月31日 · The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.

2021年7月1日 · The resulting Immunosynthen platform, which was developed specifically for the selected STING agonist payload, was used to generate XMT-2056, a tumor antigen-targeted …

2022年6月15日 · We present here a novel therapeutic agent, XMT-2056, that results in robust anti-tumor activity mediated by an immune response through targeted delivery of a STING …